|
1
|
Yin L, Duan JJ, Bian XW and Yu SC:
Triple-negative breast cancer molecular subtyping and treatment
progress. Breast Cancer Res. 22:612020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McGovern UB, Francis RE, Peck B, Guest SK,
Wang J, Myatt SS, Krol J, Kwok JM, Polychronis A, Coombes RC and
Lam EW: Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in
breast cancer. Mol Cancer Ther. 8:582–591. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Matsuda N, Lim B, Wang X and Ueno NT:
Early clinical development of epidermal growth factor receptor
targeted therapy in breast cancer. Expert Opin Investig Drugs.
26:463–479. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Peng B, He R, Xu Q, Yang Y, Hu Q, Hou H,
Liu X and Li J: Ginsenoside 20(S)-protopanaxadiol inhibits
triple-negative breast cancer metastasis in vivo by targeting
EGFR-mediated MAPK pathway. Pharmacol Res. 142:1–13. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gonzalez-Conchas GA, Rodriguez-Romo L,
Hernandez-Barajas D, Gonzalez-Guerrero JF, Rodriguez-Fernandez IA,
Verdines-Perez A, Templeton AJ, Ocana A, Seruga B, Tannock IF, et
al: Epidermal growth factor receptor overexpression and outcomes in
early breast cancer: A systematic review and a meta-analysis.
Cancer Treat Rev. 62:1–8. 2018. View Article : Google Scholar
|
|
7
|
Payapilly A and Malliri A:
Compartmentalisation of RAC1 signalling. Curr Opin Cell Biol.
54:50–56. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Su Z, Li Z, Wang C, Tian W, Lan F, Liang
D, Li J, Li D and Hou H: A novel Rhein derivative: Activation of
Rac1/NADPH pathway enhances sensitivity of nasopharyngeal carcinoma
cells to radiotherapy. Cell Signal. 54:35–45. 2019. View Article : Google Scholar
|
|
9
|
Zhou G, Peng F, Zhong Y, Chen Y, Tang M
and Li D: Rhein suppresses matrix metalloproteinase production by
regulating the Rac1/ROS/MAPK/AP-1 pathway in human ovarian
carcinoma cells. Int J Oncol. 50:933–941. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Roskoski R Jr: ErbB/HER protein-tyrosine
kinases: Structures and small molecule inhibitors. Pharmacol Res.
87:42–59. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liang D, Su Z, Tian W, Li J, Li Z, Wang C,
Li D and Hou H: Synthesis and screening of novel
anthraquinone-quinazoline multitarget hybrids as promising
anticancer candidates. Future Med Chem. 12:111–126. 2020.
View Article : Google Scholar
|
|
12
|
Klöditz K and Fadeel B: Three cell deaths
and a funeral: Macrophage clearance of cells undergoing distinct
modes of cell death. Cell Death Discov. 5:652019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Daddam JR, Dowlathabad MR, Panthangi S and
Jasti P: Molecular docking and P-glycoprotein inhibitory activity
of flavonoids. Interdiscip Sci. 6:167–175. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stivarou T and Patsavoudi E: Extracellular
molecules involved in cancer cell invasion. Cancers (Basel).
7:238–265. 2015. View Article : Google Scholar
|
|
15
|
Williams CB, Soloff AC, Ethier SP and Yeh
ES: Perspectives on epidermal growth factor receptor regulation in
triple-negative breast cancer: Ligand-mediated mechanisms of
receptor regulation and potential for clinical targeting. Adv
Cancer Res. 127:253–281. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sporikova Z, Koudelakova V, Trojanec R and
Hajduch M: Genetic markers in triple-negative breast cancer. Clin
Breast Cancer. 18:e841–e850. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Al-Mahmood S, Sapiezynski J, Garbuzenko OB
and Minko T: Metastatic and triple-negative breast cancer:
Challenges and treatment options. Drug Deliv Transl Res.
8:1483–1507. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Baselga J, Albanell J, Ruiz A, Lluch A,
Gascón P, Guillém V, González S, Sauleda S, Marimón I, Tabernero
JM, et al: Phase II and tumor pharmacodynamic study of gefitinib in
patients with advanced breast cancer. J Clin Oncol. 23:5323–5333.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
El Guerrab A, Bamdad M, Bignon YJ,
Penault-Llorca F and Aubel C: Co-targeting EGFR and mTOR with
gefitinib and everolimus in triple-negative breast cancer cells.
Sci Rep. 10:63672020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bid HK, Roberts RD, Manchanda PK and
Houghton PJ: RAC1: An emerging therapeutic option for targeting
cancer angiogenesis and metastasis. Mol Cancer Ther. 12:1925–1934.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shi Y, Su C, Cui W, Li H, Liu L, Feng B,
Liu M, Su R and Zhao L: Gefitinib loaded folate decorated bovine
serum albumin conjugated carboxymethyl-beta-cyclodextrin
nanoparticles enhance drug delivery and attenuate autophagy in
folate receptor-positive cancer cells. J Nanobiotechnology.
12:432014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kaneto N, Yokoyama S, Hayakawa Y, Kato S,
Sakurai H and Saiki I: RAC1 inhibition as a therapeutic target for
gefitinib-resistant non-small-cell lung cancer. Cancer Sci.
105:788–794. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim H, Samuel SL, Zhai G, Rana S, Taylor
M, Umphrey HR, Oelschlager DK, Buchsbaum DJ and Zinn KR:
Combination therapy with anti-DR5 antibody and tamoxifen for triple
negative breast cancer. Cancer Biol Ther. 15:1053–1060. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen Y, Chen X, Ding X and Wang Y:
Afatinib, an EGFR inhibitor, decreases EMT and tumorigenesis of
Huh-7 cells by regulating the ERK-VEGF/MMP9 signaling pathway. Mol
Med Rep. 20:3317–3325. 2019.PubMed/NCBI
|
|
25
|
Kim TI, Kim H, Lee DJ, Choi SI, Kang SW
and Kim EK: Altered mitochondrial function in type 2 granular
corneal dystrophy. Am J Pathol. 179:684–692. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Neelakantan D, Zhou H, Oliphant MUJ, Zhang
X, Simon LM, Henke DM, Shaw CA, Wu MF, Hilsenbeck SG, White LD, et
al: EMT cells increase breast cancer metastasis via paracrine GLI
activation in neighbouring tumour cells. Nat Commun. 8:157732017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nieto MA, Huang RY, Jackson RA and Thiery
JP: EMT: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim S and Lee JW: Membrane proteins
involved in epithelial-mesenchymal transition and tumor invasion:
Studies on TMPRSS4 and TM4SF5. Genomics Inform. 12:12–20. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jang MH, Kim HJ, Kim EJ, Chung YR and Park
SY: Expression of epithelial-mesenchymal transition-related markers
in triple-negative breast cancer: ZEB1 as a potential biomarker for
poor clinical outcome. Hum Pathol. 46:1267–1274. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tien Y, Tsai CL, Hou WH, Chiang Y, Hsu FM,
Tsai YC and Cheng JC: Targeting human epidermal growth factor
receptor 2 enhances radiosensitivity and reduces the metastatic
potential of Lewis lung carcinoma cells. Radiat Oncol. 15:582020.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yoon C, Cho SJ, Chang KK, Park DJ, Ryeom
SW and Yoon SS: Role of Rac1 pathway in epithelial-to-mesenchymal
transition and cancer stem-like cell phenotypes in gastric
adenocarcinoma. Mol Cancer Res. 15:1106–1116. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Santibanez JF, Obradović H, Kukolj T and
Krstić J: Transforming growth factor-β, matrix metalloproteinases,
and urokinase-type plasminogen activator interaction in the cancer
epithelial to mesenchymal transition. Dev Dyn. 247:382–395. 2018.
View Article : Google Scholar
|
|
33
|
Zhuge Y and Xu J: Rac1 mediates type I
collagen-dependent MMP-2 activation. Role in cell invasion across
collagen barrier. J Biol Chem. 276:16248–16256. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Binker MG, Binker-Cosen AA, Richards D,
Oliver B and Cosen-Binker LI: LPS-stimulated MUC5AC production
involves Rac1-dependent MMP-9 secretion and activation in NCI-H292
cells. Biochem Biophys Res Commun. 386:124–129. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cox G, Jones JL and O'Byrne KJ: Matrix
metalloproteinase 9 and the epidermal growth factor signal pathway
in operable non-small cell lung cancer. Clin Cancer Res.
6:2349–2355. 2000.PubMed/NCBI
|
|
36
|
Elkhalifa D, Siddique AB, Qusa M, Cyprian
FS, El Sayed K, Alali F, Al Moustafa AE and Khalil A: Design,
synthesis, and validation of novel nitrogen-based chalcone analogs
against triple negative breast cancer. Eur J Med Chem.
187:1119542020. View Article : Google Scholar
|
|
37
|
Martin JL, de Silva HC, Lin MZ, Scott CD
and Baxter RC: Inhibition of insulin-like growth factor-binding
protein-3 signaling through sphingosine kinase-1 sensitizes
triple-negative breast cancer cells to EGF receptor blockade. Mol
Cancer Ther. 13:316–328. 2014. View Article : Google Scholar
|
